Cargando…
Treatment of pulmonary arterial hypertension: A review of drugs available for advanced therapy
Pulmonary hypertension (PH) has traditionally been considered a rare disease with a uniformly poor prognosis. However, this was prior to the introduction of advanced therapies for this condition, and more recent registries in the treatment era have shown 5-year survival rates of up to 65%. Prior to...
Autores principales: | Wilken, E, Bennji, S, Symons, G, Williams, P G, Allwood, B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
South African Medical Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279001/ https://www.ncbi.nlm.nih.gov/pubmed/34286246 http://dx.doi.org/10.7196/SARJ.2019.v25i1.236 |
Ejemplares similares
-
Differences in health policies for drug availability in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension across Latin America
por: Orozco‐Levi, Mauricio, et al.
Publicado: (2022) -
New Drugs and Therapies in Pulmonary Arterial Hypertension
por: Shah, Aangi J., et al.
Publicado: (2023) -
Recent Advances in the Treatment of Pulmonary Arterial Hypertension
por: Otani, Naoyuki, et al.
Publicado: (2022) -
The aetiology, clinical presentation and treatment of patients with pulmonary hypertension in Cape Town: A preliminary report from the Groote Schuur Hospital Pulmonary Hypertension Registry
por: Davies-van Es, S, et al.
Publicado: (2018) -
An Update on Advancements and Challenges in Inhalational Drug Delivery for Pulmonary Arterial Hypertension
por: Agnihotri, Vinit, et al.
Publicado: (2022)